Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Hum Reprod ; 29(3): 525-33, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24345581

RESUMEN

STUDY QUESTION: How does the successful cryopreservation of semen affect the odds of post-treatment fatherhood among Hodgkin lymphoma (HL) survivors? SUMMARY ANSWER: Among 334 survivors who wanted to have children, the availability of cryopreserved semen doubled the odds of post-treatment fatherhood. WHAT IS KNOWN ALREADY: Cryopreservation of semen is the easiest, safest and most accessible way to safeguard fertility in male patients facing cancer treatment. Little is known about what proportion of patients achieve successful semen cryopreservation. To our knowledge, neither the factors which influence the occurrence of semen cryopreservation nor the rates of fatherhood after semen has been cryopreserved have been analysed before. STUDY DESIGN, SIZE, DURATION: This is a cohort study with nested case-control analyses of consecutive Hodgkin survivors treated between 1974 and 2004 in multi-centre randomized controlled trials. A written questionnaire was developed and sent to 1849 male survivors. PARTICIPANTS/MATERIALS, SETTING, METHODS: Nine hundred and two survivors provided analysable answers. The median age at treatment was 31 years. The median follow-up after cryopreservation was 13 years (range 5-36). MAIN RESULTS AND THE ROLE OF CHANCE: Three hundred and sixty-three out of 902 men (40%) cryopreserved semen before the start of potentially gonadotoxic treatment. The likelihood of semen cryopreservation was influenced by age, treatment period, disease stage, treatment modality and education level. Seventy eight of 363 men (21%) used their cryopreserved semen. Men treated between 1994 and 2004 had significantly lower odds of cryopreserved semen use compared with those treated earlier, whereas alkylating or second-line (chemo)therapy significantly increased the odds of use; no other influencing factors were identified. We found an adjusted odds ratio of 2.03 (95% confidence interval 1.11-3.73, P = 0.02) for post-treatment fatherhood if semen cryopreservation was performed. Forty-eight out of 258 men (19%) who had children after HL treatment became a father using cryopreserved semen. LIMITATIONS, REASONS FOR CAUTION: Data came from questionnaires and so this study potentially suffers from response bias. We could not perform an analysis with correction for duration of follow-up or provide an actuarial use rate due to lack of dates of semen utilization. We do not have detailed information on either the techniques used in cryopreserved semen utilization or the number of cycles needed. STUDY FUNDING/COMPETING INTERESTS: Lance Armstrong Foundation, Dutch Cancer Foundation, René Vogels Stichting, no competing interests.


Asunto(s)
Criopreservación , Fertilidad , Enfermedad de Hodgkin/terapia , Preservación de Semen , Semen , Adolescente , Adulto , Factores de Edad , Anciano , Niño , Estudios de Cohortes , Enfermedad de Hodgkin/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Sobrevivientes
2.
Med Phys ; 37(12): 6292-9, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21302785

RESUMEN

PURPOSE: To avoid complications in total body irradiation (TBI), it is important to achieve a homogeneous dose distribution throughout the body and to deliver a correct dose to the lung which is an organ at risk. The purpose of this work was to validate the TBI dose protocol and to check the accuracy of the 3D dose calculations of the treatment planning system. METHODS: Dosimetry based on alanine/electron paramagnetic resonance (EPR) was used to measure dose at numerous locations within an anthropomorphic phantom (Alderson) that was irradiated in a clinical TBI beam setup. The alanine EPR dosimetry system was calibrated against water calorimetry in a Co-60 beam and the absorbed dose was determined by the use of "dose-normalized amplitudes" A(D). The dose rate of the TBI beam was checked against a Farmer ionization chamber. The phantom measurements were compared to 3D dose calculations from a treatment planning system (Pinnacle) modeled for standard dose calculations. RESULTS: Alanine dosimetry allowed accurate measurements which were in accordance with ionization chamber measurements. The combined relative standard measurement uncertainty in the Alderson phantom was U(r)(A(D))=0.6%. The humanoid phantom was irradiated to a reference dose of 10 Gy, limiting the lung dose to 7.5 Gy. The ratio of the average measured dose midplane in the craniocaudal direction to the reference dose was 1.001 with a spread of +/- 4.7% (1 sd). Dose to the lung was measured in 26 locations and found, in average, 1.8% lower than expected. Lung dose was homogeneous in the ventral-dorsal direction but a dose gradient of 0.10 Gy cm(-1) was observed in the craniocaudal direction midline within the lung lobe. 3D dose calculations (Pinnacle) were found, in average, 2% lower compared to dose measurements on the body axis and 3% lower for the lungs. CONCLUSIONS: The alanine/EPR dosimetry system allowed accurate dose measurements which enabled the authors to validate their TBI dose protocol. Dose calculations based on a collapsed cone convolution dose algorithm modeled for regular treatments are accurate within 3% and can further be improved when the algorithm is modeled for TBI.


Asunto(s)
Alanina , Fantasmas de Imagen , Dosis de Radiación , Radiometría/instrumentación , Planificación de la Radioterapia Asistida por Computador/instrumentación , Irradiación Corporal Total/métodos , Espectroscopía de Resonancia por Spin del Electrón , Humanos , Dosificación Radioterapéutica
3.
Br J Cancer ; 101(4): 628-36, 2009 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-19672265

RESUMEN

BACKGROUND: The aim of this study was to evaluate the radiosensitising effect of gemcitabine, in terms of cell-cycle progression, induction of apoptosis, and to investigate the molecular events regulating apoptosis. METHODS: Tumour cells were treated with gemcitabine, radiation, or the combination. 0-72 h after treatment, cells were collected for cell-cycle analysis and apoptosis determination. Caspase 8 and 9, Bid and tBid expression were determined by western blot. The mitochondrial membrane potential was determined using flow cytometry. An RT(2) Profiler PCR Array for human apoptotic genes was performed after the combination or TRAIL treatment. RESULTS: Gemcitabine and radiation resulted in an early S-phase block immediately after treatment, after which the cells moved synchronously through the cell cycle. When cell-cycle distribution returned to pre-treatment levels, an increased induction of apoptosis was observed with activation of caspase 8 and 9 and a reduction of the mitochondrial membrane potential. Gene expression after treatment with radiosensitising conditions was comparable with expression after the TRAIL treatment. CONCLUSION: A role for the cell-cycle perturbations and the induction of apoptosis could be attributed to the radiosensitising effect of gemcitabine. Apoptosis induction was comparable with the apoptotic pathway observed after the TRAIL treatment, that is the involvement of the extrinsic apoptosis pathway.


Asunto(s)
Apoptosis/efectos de los fármacos , Desoxicitidina/análogos & derivados , Fármacos Sensibilizantes a Radiaciones/farmacología , Apoptosis/fisiología , Apoptosis/efectos de la radiación , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/efectos de los fármacos , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/metabolismo , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/efectos de la radiación , Western Blotting , Caspasa 8/efectos de los fármacos , Caspasa 8/metabolismo , Caspasa 8/efectos de la radiación , Caspasa 9/efectos de los fármacos , Caspasa 9/metabolismo , Caspasa 9/efectos de la radiación , Línea Celular Tumoral , Desoxicitidina/farmacología , Activación Enzimática/efectos de los fármacos , Activación Enzimática/efectos de la radiación , Citometría de Flujo , Humanos , Etiquetado Corte-Fin in Situ , Potencial de la Membrana Mitocondrial , Reacción en Cadena de la Polimerasa , Gemcitabina
4.
Cancer Treat Rev ; 33(7): 616-21, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17222514

RESUMEN

The cure rate of cancer in adolescents is high but between 10% and 40% of them will develop incurable disease depending on tumor type and prognostic factors. These patients will need palliative care defined as supportive care to optimize comfort, function and social support of the patient and the family. Palliative care should include attention to symptom control, psychosocial and spiritual issues and should be given by a multidisciplinary team. Palliative care in adolescents should also take care of the specific physical and psychosocial developmental changes in this age group. Furthermore, specific spiritual, ethical and legal issues have to be taken into account.


Asunto(s)
Neoplasias/terapia , Cuidados Paliativos/organización & administración , Adolescente , Humanos
6.
In Vivo ; 5(4): 301-6, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1810413

RESUMEN

Seven rat bronchial cancers of various grades of differentiation were used to study responses to single doses of cytostatic drugs (mitomycin C, cisplatin, methotrexate, TCNU, CCNU, ifosfamide) when growing subcutaneously or in the lung. The endpoint was growth delay as calculated from tumour volume measurements using vernier callipers or radiography. Substantial differences were observed between the tumour lines in their response to the chemotherapeutic agents. The response of tumours implanted in the lung was less than that of flank implants of the same tumour line. TCNU and ifosfamide were the most consistently effective drugs, yielding growth delays of at least two tumour volume doubling times in the majority of the lines studied.


Asunto(s)
Antineoplásicos/farmacología , Neoplasias de los Bronquios/tratamiento farmacológico , Administración Oral , Animales , Cisplatino/farmacología , Doxorrubicina/farmacología , Femenino , Humanos , Ifosfamida/farmacología , Recién Nacido , Inyecciones Intravenosas , Lomustina/farmacología , Pulmón/patología , Metotrexato/farmacología , Mitomicina/farmacología , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Inducidas por Radiación/tratamiento farmacológico , Compuestos de Nitrosourea/farmacología , Ratas , Ratas Endogámicas , Piel/patología , Taurina/análogos & derivados , Taurina/farmacología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA